Rocket Pharmaceuticals is facing a significant legal challenge as shareholders launch a class action lawsuit against the company. The lawsuit seeks to recover losses incurred by investors who were allegedly misled by Rocket’s management between February 27, 2025, and May 26, 2025. The crux of the case revolves around Rocket’s failure to disclose critical changes to the clinical trial protocol of its RP-A501 study, which included the introduction of a new immunomodulatory agent. This omission, coupled with the tragic death of a trial participant, has placed Rocket under the scrutiny of both the FDA and its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The controversy erupted when Rocket announced that the FDA had imposed a clinical hold on its RP-A501 Phase 2 pivotal study after a patient suffered a Serious Adverse Event (SAE), ultimately resulting in death. The revelation that Rocket had amended the trial protocol months before without informing shareholders has fueled allegations of securities fraud. The fallout was immediate, with Rocket’s stock price plummeting from $6.27 to $2.33 per share in a single day, marking a staggering 37% decline.
For those who have suffered financial losses during this period, there is an opportunity to seek recovery. Affected investors are encouraged to visit the following link to learn more about their rights: https://zlk.com/pslra-1/rocket-pharmaceuticals-inc-lawsuit-submission-form?wire=18. Participation in the lawsuit comes with no cost or obligation.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171